NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Topic selection and scoping

GID-MT566 Faecal microbiota transplant for recurrent or refractory *Clostridioides difficile* infection

The impact on equality has been assessed during this evaluation according to the principles of the <u>NICE Equality scheme</u>.

1. Have any potential equality issues been identified during the development of the topic briefing note or during selection, and, if so, what are they?

No equality issues have been identified but a number of equality considerations were listed:

C. difficile infections are more likely to occur in people over 65, people with certain underlying health conditions, and people with a weakened immune system. Published guidelines make recommendations for the use of Faecal microbiota transplant (FMT) for treating *C. difficile* infections in adults but not children due to limited evidence availability. FMT may not be appropriate for some people with an anaphylactic food allergy. An FMT procedure can be offered with caution to people who are immunocompromised and people with inflammatory bowel disease (IBD) should be warned of the small risk of exacerbating their IBD symptoms. Some of these people may be classed as disabled under the Equality Act. Diet and alcohol consumption of potential donors may also be considered as a barrier of having an FMT procedure for people from some faith groups. Disability, age and religion or belief are protected characteristics under the Equalities Act 2010.

2.	What is the preliminary view as to what extent these potential equality issues
	need addressing by the committee?

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes, a sentence on the limited evidence around the use of in FMT in children has been added to the decision problem.

Equality impact assessment (guidance scoping): Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection

N/A

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
Nor	ne

Approved by Associate Director: Anastasia Chalkidou

Date: 20/09/2021